Validive®

Quarterly information as of September 30, 2013

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of Orphan Oncology Products and to Supportive Care Products, today published the major key milestones achieved during the third quarter of 2013. July was marked by a successful capital increase which enabled the Company to raise a net amount of €8.4 million and showed strong support…read more →

First meeting of the International Advisory Board on oral mucositis and development of Validive®

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company dedicated to the development of orphan oncology products and to supportive care products, held the first meeting of its international Advisory Board dedicated to oral mucositis and to the associated clinical development program with Validive® (clonidine Lauriad®). This multidisciplinary Advisory Board is composed of internationally recognized European and American experts,…read more →

BioAlliance Pharma launches a capital increase of €8 million with maintenance of preferential subscription rights to accelerate the development of the two major orphan products (Livatag® and Validive®)

Issue price: 3.50 € Subscription commitment of €5 million from two reference shareholders (representing 63% of the issue) 1 new share issued for 8 existing shares The subscription period will run from July 2, 2013 to July 12, 2013 on BioAlliance Pharma SA (Euronext Paris – BIO — FR0010095596), an innovative Company dedicated to orphan oncology products and specialty products,…read more →

BioAlliance Pharma announces the initiation of the phase II clinical trial with Validive® in the United States

BioAlliance Pharma SA (Euronext Paris – BIO), a Company dedicated to the development of orphan oncology products and supportive care products, announces the initiation of its Phase II clinical trial evaluating the efficacy and safety of Validive® (clonidine Lauriad®) in the United States in patients with chemoradiation therapy-induced oral mucositis with head and neck cancer, as scheduled in the advancement…read more →

Bioalliance Pharma updates on major achievements of 2012 and publishes its 2012 consolidated financial statements and income for Q1 2013

Successful key milestones reached on all orphan oncology clinical programs First registration of Sitavig granted in European countries Oravig licensing agreement signed for US Income growth and operating costs under control. Paris, April 15, 2013 – BioAlliance Pharma SA (Euronext Paris – BIO), an innovative company dedicated to the development of orphan oncology products and to supportive care products today…read more →

BioAlliance Pharma announces the forthcoming extension of its phase II clinical trial with Validive® in the United States

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products and to supportive care products, announces the extension of its phase II clinical trial with Validive® (clonidine Lauriad™) in the United States in radio/chemotherapy-induced oral mucositis prevention in patients with head and neck cancer. Further to approval by the United States FDA…read more →

12